



## Pharmacokinetics and Pharmacodynamics of Antibacterial and Antivirulence Drugs

Guest Editor:

**Dr. Katharina Rox**

Helmholtz Centre for Infection  
Research (HZI), Braunschweig,  
Germany

Deadline for manuscript  
submissions:

**closed (31 July 2023)**

### Message from the Guest Editor

In 2017, the WHO published a list of bacteria, including but not limited to the so-called ESKAPE pathogens, for which research of new antibiotics is of critical or high priority as a result of increasing antimicrobial resistance. Currently, less than 50 new antibacterial compounds have been investigated in clinical trials. This highlights that compounds with novel mechanisms of action are desperately needed. To enable translation from bench to bedside, novel compounds must first prove that they reach their target site, and that they are effective under in vitro and in vivo infection conditions. In addition to novel treatment options, more sophisticated treatment regimens of current antibacterial agents can help to lower the risk of rapid emergence of antimicrobial resistance. Therefore, the main goal of this Special Issue is to present contributions of novel approaches to fighting antimicrobial resistance as well as strategies to ameliorate current treatment regimens in human medicine.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi